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Abstract. Gamma-emitting radiopeptides are useful for 
scintigraphy of tumours on the basis of receptor binding. 
Likewise, R-emitting radiopeptides may be used in ra- 
dionuclide therapy of such tumours. As iodine-131 sug- 
gested to be suitable for this purpose, experiments were 
performed using three somatostatin a alogues, in which 
the effects of coupling of a therapeutic dose of ~31I to 
such peptides were investigated. This study deals with 
the radioiodination f very small amounts of peptide on 
a therapeutic scale, the required purification procedures 
after adioiodination, and the influence of high beta flux- 
es from 131I on a peptide during radioiodination a d pu- 
rification. Based on the regularly used therapeutic doses 
of ~31I in cancer treatment and our previous experience 
with [lllIn-DTPA-D-Phel]-octreotide, it was assumed 
that a minimal effective therapeutic dose of 3.7 GBq 131I 
has to be coupled to a maximum of =100 gg peptide, 
representing only a slight excess of peptide over 13~I. 
This contrasts with non-peptide radiopharmaceuticals in 
which high compound to radionuclide ratios are usually 
used. Labelling at low peptide to radionuclide ratios 
(low labelling yields) results in the formation of di-iodi- 
nated compounds, whereas at high peptide to radionu- 
clide ratios (high labelling yields) mono-iodinated prod- 
ucts of low specific activity are formed. Thus, after ra- 
dioiodination the desired mono-iodinated peptide has to 
be separated from unreacted iodide, and from di-iodina- 
ted and unreacted peptide, as both compounds compete 
for the receptors. Possible radiolysis of the peptide dur- 
ing labelling and separation steps were investigated by 
irradiating 30 gg unlabelled peptide with 370 MBq 131I 
in a small volume. The peptide composition of the incu- 
bation mixtures was investigated by high-performance 
liquid chromatography after irradiation for 30 min to 
24 h. The results showed that the peptide was degraded 
with a half-life of less than 1 h. During the preparation 
of a real therapeutic dose (at much higher R-flux) the 
peptide will be degraded even faster during the various 
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steps required. In conclusion, intact mono-iodinated 131[_ 
labelled somatostatin analogues for peptide receptor 
therapy will be difficult o obtain. 
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Introduction 
Recently, increasing attention has been paid to scintigra- 
phy of various processes containing receptors for peptide 
hormones by the application of radiolabelled analogues 
of these hormones. Following [123I-Tyr3]-octreotide, 
[111In-DTPA-D-Pheq-octreotide (known as Octreoscan 
111) is nowadays extensively used for scintigraphy of 
somatostatin receptor-positive tumours [1-3]. Further- 
more, an increasing number of publications i reporting 
on the use of other adioactive peptides for scintigraphic 
demonstration of various tumours and infectious pro- 
cesses [4-9]. In the case of high tumour accumulation, 
such peptides may also be used for radionuclide therapy, 
similar to 131I-iodide in the treatment of thyroid cancer 
and 131I-metaiodobenzylguanidine (MIBG) in the treat- 
ment of neuroblastoma and phaeochromocytoma. 
Obviously, 131I has been proposed for labelling of so- 
matostatin analogues for radionuclide therapy of so- 
matostatin receptor-positive tumours [10, 11]. We as- 
sume that for radionuclide therapy with 13tI-labelled 
peptides imilar doses as are used in 131I-iodide [12] and 
131I-MIBG therapy [13] will be required. Usually, only a 
limited amount of a bioactive peptide hormone can be 
administered without pharmacological side-effects, 
which may become a limiting factor in the coupling of a 
therapeutic amount of radionuclide to such a peptide. 
Therefore, for safety reasons it has been deemed advis- 
able not to exceed the 100 gg dose range in i.v. adminis- 
tration of radiolabelled somatostatin a alogues. Further- 
more, with 100 gg i.v. octreotide, somatostatin receptors 
will become saturated. Based on our experience with 
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Tab le  1. Molar ligand to radionuclide ratios for some therapeutic 
radiopharmaceuticals 
Treatment of: Radionuclide Compound Excess of 
(radioactivity (mass) compound 
and mass) over 
radionuclide 
Pain 186Re HEDP 
1295 MBq 5 mg 
4.7x10 -8 tool 2x10 -5 tool 430 
Neuroblas- t31I MIBG 
toma 3700 MBq 3.3 mg 
3.8x10 -8 tool 8x10 -6 tool 210 
Various 1311 MoAb 
malignancies 3700 MBq 20 mg 
3.8x10 -8 mol 1.3x10 -7 tool 3.4 
MoAb fragment 
20 mg 
4.0x10 7 tool 11 
90y MoAb 
3700 MBq 20 mg 
2.1x10 -9 tool 1.3x10 7 tool 60 
MoAb 
fragment 
20 mg 
4.0x10 v tool 190 
Endocrine 11t in  DTPA-octreotide 
tumours 3700 MBq 100 gg 
2.2x10 -9 mol 6.7x10 -8 tool 30 
13ti Peptide 
3700 MBq 100 gg 
3.8x10 -8 mot 6.7x10 -8 tool 1.75 
[ l~l In-DTPA-D-Phel]-octreotide [14, 15], it was estimat- 
ed that an effective therapeutic dose of =3.7 GBq (38 
nmol) 131I has to be coupled to =100 gg (67 nmol) of  a 
somatostatin analogue (M=l.5 kDa), i.e. nearly a two- 
fold excess of peptide over radionucl ide. This is in sharp 
contrast o the high molar compound to radionucl ide ra- 
tios of most radiopharmaceuticals.  Table 1 shows these 
ratios for some radiotherapeutic agents. However, as de- 
scribed previously [16], radioiodinat ion of  [Tyr3]-octreo - 
tide using only a small excess of  peptide over radionu- 
cl ide results in a considerable amount of di - iodinated 
[Tyr3]-octreotide, which no longer binds to the somato- 
statin receptor [17]. Therefore, we investigated the re- 
sults of  radiolabel l ing of  two somatostatin analogues, 
[Tyr3]-octreotide and [DTPA-D-Phel]-RC-160 (Fig. 1), 
at different molar peptide to nucl ide ratios, simulating 
condit ions during the preparat ion of  a therapeutic dose. 
125I was used as a model  for ~31I because of  its wel l-  
characterized specific radioactivity. 
During the necessary high-performance l iquid chro- 
matography (HPLC) and/or SEP-PAK purif ication steps 
after label l ing on a therapeutic scale with 131I, high beta 
fluxes originate due to the concentration of the radiola- 
r 1 
A D-Phe-Cys-Tyr-D-Trp-Lys-Thr-Cys-Thr(ol) 
[ 1 
DTPA-D-Phe-Cys-Tyr-D-Trp-Lys-Val-Cys-Trp-NH2 
r i 
C DTPA-D-Phe-Cys-Phe-D-Trp-Lys-Thr-Cys-Th r(ol) 
Fig. 1. Structural formulae of [Tyr3]-octreotide (A), [DTPA-D- 
Phet]-RC-160 (B) and [DTPA-D-Phel]-octreotide (C)
bel led peptides in narrow zones of column material. 
Therefore, radiolyt ic effects under therapeutic ircum- 
stances were simulated by exposing unlabel led peptide 
in a small volume to a high dose of  13q-beta radiation 
over various t ime intervals. Afterwards, the radiation 
damage was investigated by HPLC. 
Materials and methods 
Peptides. [Tyr3]-octreotide and [DTPA-D-PheJl-octreotide were 
obtained from Sandoz (Basle, Switzerland) and [DTPA-D-Phel] - 
RC-160 from Sanbio (Uden, The Netherlands). 
Quality control of unlabelled peptides. The original peptides were 
analysed by reversed-phase HPLC with a Waters 600 E multisol- 
vent delivery system connected to a g-Bondapak-Cl8 reversed- 
phase column (300x3.9 ram, particle size 10 gin) with UV detec- 
tion (254 nm). Elution was carried out at a flow rate of 1 ml/min 
with a linear gradient of 40%-80% (v/v) methanol in 50 mM Na- 
acetate buffer (pH 5.5) for 20 rain and the composition was main- 
tained for another 5 rain. 
Radioiodination ofpeptides and quality control of radioiodinated 
peptides. [Tyr3]-octreotide and [DTPA-D-Phel]-RC-160 were ra- 
dioiodinated with 125I as described previously [16]. [Tyr3]-octreo - 
tide (4.3-105 gg) was labelled with 125I (92.5-370 MBq), corre- 
sponding to molar peptide to radionuclide ratios of 1.7-43. 
[DTPA-D-Phea]-RC-160 (1.3-1251.tg) was labelled with 125I 
(37-370 MBq), corresponding to molar peptide to radionuclide ra- 
tios of 1.7-31. 
After radiolabelling, the peptide components in the reaction 
mixture were isolated on a SEK-PAK C18 reversed-phase extrac- 
tion cartridge as described previously [16], and analysed with the 
HLPC system described above. Eluted radioactivity was moni- 
tored on-line using an NaI probe connected to a Canberra single- 
channel analyser with a recorder. Collected fractions were mea- 
sured by routine scintillation counting. Isolated peaks were con- 
centrated and reinjected into the HPLC system in order to confirm 
the integrity of the radiolabelled peptide. 
Investigation of radiolysis of peptides during purification steps. 
The effects of high beta fluxes emanating from a therapeutic dose 
of 131I on microgram amounts of unlabelled peptide were investi- 
gated, simulating eometrical conditions during the mandatory 
purification steps. For this purpose [DTPA-D-Phel]-octreotide was 
used, as only of this octreotide analogue was sufficient pure com- 
pound available. In nine different irradiation experiments a well- 
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defined amount of 131I (370 MBq in 167 ~tl 0.05 M phosphate) 
was incubated for 0.5-24 h at room temperature with [DTPA-D- 
Phel]-octreotide (30 ~tg in 150 gl 0.05 M acetic acid) in a small 
polyethylene cup. The radiation absorbed ose in the reaction vol- 
ume amounted to 130 Gy/h. Radiolysis under these circumstances 
was investigated by HPLC with UV detection of the unlabelled 
peptide and its degradation products at 254 nm. In a control exper- 
iment in the absence of 1311, the stability of the peptide was tested 
at room temperature without irradiation. 
Results 
Peptide composition before and after radioiodination 
The HPLC elution pattern (monitored at 254 nm) of 
[Tyr3]-octreotide showed one peak (data not shown), 
while those of [DTPA-D-Phel]-RC-160 and [DTPA-D- 
Phel]-octreotide consisted of three peaks (data not 
shown), corresponding to the data reported by the manu- 
facturers. 
Peptide radiolabelling yields amounted to 31%-93% 
as measured by SEP-PAK elution. Typical examples of 
the radioactive peptide composition i  the reaction mix- 
tures with different molar peptide to radioiodide ratios 
are shown in Fig. 2 ([Tyr3]-octreotide) and Fig. 3 
([DTPA-D-Phel]-RC-160). At molar peptide to 125I ratios 
of 41, 3.5 and 1.7, radioiodination of [Tyr3]-octreotide 
yielded 96%/4%, 75%/25% and 60%/40% mono-/di-io- 
dinated peptide, respectively. In the case of labelling of 
[DTPA-D-Pheq-RC-160 at molar peptide to 125I ratios of 
17 and 1.7, 82% and 56% of the labelled peptides were 
mono-iodinated, respectively. Thus, at higher molar pep- 
tide to radionuclide ratios far more mono-iodinated than 
di-iodinated peptides are formed. In the case of [DTPA- 
D-Phe 1]-RC- 160, the HPLC elution profile of the mono- 
iodinated compound shows three peaks, like that of the 
original unlabelled compound. After reinjection of each 
of these three peaks into the HPLC the same three origi- 
nal peaks were again observed, indicating that this pep- 
tide exists in three interconvertable forms (data not 
shown). 
m 
m i l l  
d 
A B C 
Fig. 2. Typical HPLC elution patterns of the reaction mixtures af- 
ter radioiodination of [Tyr3]-octreotide at three different molar 
peptide to radionuclide ratios - 43 (A), 3.5 (B) and 1.7 (C) - mea- 
sured by on-line gamma counting, m, Mono-iodinated peptide; d, 
di-iodinated peptide 
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Fig. 3. Typical HPLC elution patterns of the reaction mixtures af- 
ter radioiodination of [DTPA-D-Phel]-RC-160 at two different 
molar peptide to radionuclide ratios - 17 (A) and 1.7 (B) - mea- 
sured by on-line gamma counting, m, Mono-iodinated peptide; d, 
di-iodinated peptide 
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Fig. 4. Typical HPLC elution patterns before (A) and 30 rain (B) 
and 4 h (C) after irradiation of 30 gg [[DTPA-D-Pheq-octreotide 
by 370 MBq 131I iodide, measured by UV absorption at 254 nm. 
o, Original peptide; dp, degradation products 
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Fig. 5. Remaining [DTPA-D-Phel]-octreotide after irradiation by 
L31I as a function of time expressed as a percentage of the original 
amount, measured by UV absorption at 254 nm 
Radiolysis by high beta-fluxes 
In Fig. 4 the degradation of [DTPA-D-Pheq-octreotide 
by the beta radiation of 131I is shown under circumstanc- 
es approaching those occurring during separation steps. 
The figure shows the HPLC elution profiles of the origi- 
nal (unlabelled) compound and the irradiation mixture 
after 30 rain and 4 h of irradiation. After irradiation new 
peaks with shorter etention times are formed while the 
peak of the original peptide declines. After 24 h no orig- 
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inal peptide nor any degradation product was detected in 
the HPLC eluate (data not shown). The irradiation ex- 
periment shows that the original peptide is destroyed un- 
der these conditions with a half-life of less than 1 h (Fig. 
5). In a control experiment the peptide remained intact 
for 24 h at room temperature in the absence of 131I (data 
not shown). 
Discussion 
With the growing number of publications on somatosta- 
tin receptor scintigraphy, the question arises as to wheth- 
er peptides also may be used in radionuclide therapy of 
somatostatin receptor-positive l sions. Usually, radio- 
pharmaceuticals are prepared using a high compound to 
radionuclide ratio, resulting in labels with low specific 
activity. Because in most instances radionuclide therapy 
is based on mechanisms with high accumulation capaci- 
ty, this is usually no drawbacks. Thus, radionuclide ther- 
apy is usually not limited by the mass of the adminis- 
tered radiopharmaceutical. However, in radionuclide re- 
ceptor therapy a much higher specific activity is re- 
quired. As in this case compounds are accumulated by 
specific, saturable receptor binding, efficient radionu- 
clide receptor therapy requires an optimal mass of pep- 
tide with sufficient activity of a suitable radionuclide. 
Depending on the physical characteristics of the radio- 
nuclide and the metabolic properties of the radiolabelled 
compound, radionuclide receptor therapy requires a sim- 
ilar amount of radiation as is used in radioiodide therapy 
of thyroid cancer, i.e. equivalent to a minimal dose of 
3700 MBq 131I. Such a dose has to be coupled with a 
small amount of peptide. 
Optimal mass of peptide 
In order to deliver the highest possible radiation dose to 
a tumour, an optimal mass of peptide labelled with high 
activity is required. This mass is dependent on various, 
often unknown, parameters, uch as saturation (adminis- 
tered mass and endogenous peptide) and up- or down- 
regulation of receptors at higher peptide doses. Ligand- 
specific accumulation of [111in_DTPA_D_Phel]_octreo_ 
tide in somatostatin receptor-positive tissues was initial- 
ly increased by injecting more peptide [18]. Similar ob- 
servations howed enhanced visualization of tumours in 
patients during octreotide treatment [19-22]. Scintigra- 
phy after administration of [llqn_DTPA_D_Phel]_octreo_ 
tide with different amounts of unlabelled [DTPA-D- 
Phea]-octreotide suggested an optimal range of 5-120 gg 
(3.3-80 nmol) peptide [14]. When [llqn-DTPA-D-Phel]- 
octreotide was used therapeutically for the first time, it 
was in this same dose range [15]. However, routine oct- 
reotide treatment is performed with daily subcutaneous 
doses of several hundred micrograms of octreotide, 
probably causing upregulation of receptors [19-22]; 
consequently octreotide in blood will not attain the level 
reached after i.v. administration of 100 gg, as is used in 
radionuclide therapy. Intravenous administration of high- 
er doses of (nnlabelled) peptide will therefore only satu- 
rate receptors without the desired radiotherapeutic ef- 
fect. Furthermore, not only receptor occupation but also 
unwanted pharmacological side-effects may limit the ad- 
ministration of bioactive peptides. Therefore, the highest 
radionuclide tumour uptake (% dose) is assumed to be 
achieved with 100 gg (67 nmol) of 1.5-kDa somatostatin 
analogue. Independent of the used radionuclide, an 
equivalent mass of radiolabelled somatostatin analogue 
will thus be required for radionuclide therapy, assuming 
that its metabolic properties are comparable to those of 
[111in_DTPA_D_Phel]_octreotide. 
Choise of a suitable radionuclide 
Recently, in addition to radionuclides emitting medium- 
and high-energy beta particles, attention has been paid to 
radionuclides that are commonly used for gamma cam- 
era scintigraphy. It is suggested that these radionuclides 
may also find therapeutic use on the basis of their low 
energetic onversion and Auger electrons. The radiation 
energy of these electrons is deposited within the direct 
vicinity of the disintegrating radionuclide. This category 
includes gallium-67 and indium-111 [23-26]. The ques- 
tion arises as to whether such a radionuclide, coupled to 
a peptide, is sufficiently internalized by the cell that the 
emitted low-energy particles will reach the nucleus. That 
this may be the case was suggested by the successful 
treatment of a glucagonoma patient with [111In-DTPA-D- 
Phel]-octreotide [15]. In this study we paid attention to 
the possibility of preparing and purifying radioiodinated 
peptides for peptide receptor therapy because 131I-iodide 
is most frequently used in therapeutic nuclear medicine 
(for the treatment of hyperthyroidism, goitre and thyroid 
cancer). In the form of 131I-MIBG, 131I is successfully 
used in treatment of neuroblastoma and phaeochromocy- 
toma. 
Labelling of peptides with 1MI 
The proposed 3.7 GBq 131I (38 nmol, see Table 2) iodide 
must be bound to the presumed optimal mass (100 
gg=67 nmol peptide). Incorporation of more than one io- 
dine atom into the tyrosine of [Tyr3[-octreotide r sults in 
the loss of receptor binding [17]. Although the use of 
131I is more appropriate to test the different labelling 
conditions, this radionuclide is not available in the well- 
defined specific activity required for the molar-ratio ex- 
periments. Therefore, 125I was used as a model because 
of its known specific activity (8xl 0 x6 Bq/mol). 
Our peptide experiments with 125I demonstrate that 
low excesses of peptide over radionuclide result in rela- 
tively large fractions of di-iodinated compounds, while a 
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Table 2. Theoretical (=lowest) 
and practical masses of 3.7 GBq 
radionuclide 
Radio- Theory Practice 
nuclide (nmol) (nmol) 
13tI 6.17 38.2 
90y 2.07 2.07 
186Re 2.91 133 
3~p 11 11 
114rain 38.3 ? 
I61Tb 5.29 ? 
67Ga 2.53 2.53 
ltlIn 2.17 2.17 
125I 46.0 46.0 
large excess of peptide over radionuclide mainly causes 
the formation of the mono-iodinated compounds (Figs. 
2, 3), with, of course, much peptide remaining unla- 
belled. Preparative HPLC separations will therefore be 
required to separate the wanted radiopeptide from unla- 
belled peptide, di-iodinated peptide and unreacted radio- 
iodide. The radiopeptide is concentrated in very small 
volumes during necessary purification on HPLC and/or 
SEP-PAK columns and, hence, is subject o radiolytic 
damage (Fig. 5). Radiolytic damage can be prevented 
using a suitable radiation quencher such as gentisic acid 
[27], but its radiation quenching effect cannot be guaran- 
teed during the SEP-PAK and HPLC purification steps. 
Therefore, 131I seems unsuitable for radionuclide so- 
matostatin receptor therapy. An additional drawback of 
the use of radioiodine for peptide receptor therapy is that 
13JI will be released from tumours in the same way as 
such release occurs after the administration f antibody 
fragment-bound radioiodine [28]. Conversely, radiomet- 
als that are chelated to antibody fragments end to be re- 
tained by tumours [28]. Therefore, in the following, a 
one-step alternative approach will be discussed in which, 
instead of 131I, residualising radiometals, uch as yttri- 
um, are used in the presence of a radiation quencher. 
Direct radiolabelling of chelator-coniugated peptides 
with radiometals 
A well-known method in the daily practice of nuclear 
medicine is the simple one-step preparation of radio- 
pharmaceuticals that does not require additional purifi- 
cation steps. Such direct radiolabelling can be performed 
in the presence of a suitable radiation quencher and will 
therefore be preferred for preparing radiopeptides for 
therapy. Peptides and proteins conjugated with polyami- 
nopolycarboxylic acids such as EDTA, DTPA and 
DOTA are suitable for such a one-step labelling proce- 
dure with radiometals. 11Tin and 90y are frequently used 
to label proteins conjugated with DTPA groups for diag- 
nostic and therapeutic purpose respectively. Although 
the binding between 90y and DTPA appeared to be sta- 
ble in vitro, this radionuclide is released from the DTPA 
group in vivo, resulting in unfavourable bone accumula- 
tion [29]. This is especially the case when one acetic ac- 
id group of DTPA is linked to the protein and, hence, is 
not available for 90y complexation [29]. In carbon back- 
bone-linked DTPA groups, such as SCN-Bz-DTPA, 90y 
is far more tightly bound under physiological conditions, 
probably because all five carboxyl groups participate in
90y complexation. I  addition, peptides may also be der- 
ivatized with polyazamacrocycles, such as the DOTA 
group, that bind 90y with very high affinity [30]. Recent- 
ly, preliminary animal experiments with an octadentate 
octreotide derivative labelled with 90y showed promis- 
ing results with respect to in vivo stability as well as in- 
hibition of tum0ur growth [31 ]. 
Furthermore, somatostatin a alogues have been cou- 
pled successfully with rhenium-188 using a 188W/188Re 
generator and routine kit coupling, although metabolic 
properties (hepatobiliary clearance and low tumour to 
normal tissue ratios) will limit their use in humans [32, 
33]. Other therapeutic radiometals suitable for one-step 
radionuclide coupling, such as terbium-161 (included in 
the DTPA group), are not yet generally available. 
In the absence of a convenient and suitable method 
for obtaining 131I-labelled peptides, the one-step label- 
ling procedure using chelator-conjugated peptides to 
bind beta-decaying radiometals, uch as 90y, l l4mIn (de- 
caying to the ~-emitting 114In) and 161Tb, will be the cur- 
rent method of choise, although the availability of ultra- 
pure radionuclides i still limited. Such radiolabelling 
will have to meet he same specific activity requirements 
as are described above (i.e. the highest possible activity 
of a radionuclide coupled to the optimal mass of pep- 
tide), which seems possible for many short-lived radio- 
nuclides in the absence of their isotopes and other metal- 
lic contaminants. In Table 2 the theoretical numbers of 
mols corresponding to 3.7 GBq of some radionuclides 
are compared with the attainable values in practice. This 
illustrates that certainly not all short-lived radionuclides 
will reach the high therapeutic specific activity required 
for coupling a high therapeutic radionuclide dose to a 
relatively small amount of peptide. 90y is a good candi- 
date in this respect, but few if any peptides are available 
conjugated with a suitable chelator such as the DOTA 
group. Our preliminary experience shows that ~61Tb 
binds well to [DTPA-D-Phel]-octreotide [34] and may be 
suitable for radionuclide receptor therapy. Finally, the 
problem of high physiological ccumulation f chelator- 
conjugated radiopharmaceuticals in vital organs, such as 
the kidneys, deserves further investigation. 
Conclusion 
Intact mono-iodinated 13~I-labelled somatostatin ana- 
logues are hard to obtain in radiotherapeutic amounts, 
since further separations are necessary during which ra- 
diation damage to the peptide will occur due to enrich- 
ment of the radionuclide in small volumes. For peptide 
receptor radionuclide therapy direct labelling of a radio- 
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metal such as 90y or a61Tb to a chelator-conjugated p p- 
tide in the presence of a suitable radiation quencher ap- 
pears far more easily attainable. A second advantage 
may be that radiometals will probably be better etained 
in tumours than radioiodine. However, many problems 
regarding radionuclide purity and synthesis of suitable 
chelator-conjugated p ptides remain to be solved. 
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